---
layout: entry
title: "Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo"
link: "https://doi.org/10.1038/s41392-020-0176-0"
author:
- Deng, Wei; Xu, Yanfeng; Kong, Qi; Xue, Jing; Yu, Pin; Liu, Jiangning; Lv, Qi; Li, Fengdi; Wei, Qiang; Bao, Linlin

summary:
- "Until now, no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection. Existing medicines have some strong advantages on pharmacokinetics, known side effects, safety and dosing regimens. No medicine candidates have been evaluated in vivo by using animal models with the disease. Vaccines and vaccines are not available to prevent infection in vitro. Coronavirus disease 2019 has swept through the world with more than 3 million confirmed cases."

original:
- "Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly swept through the worldwide, with more than 3 million confirmed cases. Until now, no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection. Existing medicines have some strong advantages on pharmacokinetics, known side effects, safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection."
---

